Nitric oxide (SB 204)

Drug Profile

Nitric oxide (SB 204)

Alternative Names: NVN-1000; SB-204

Latest Information Update: 02 Feb 2017

Price : $50

At a glance

  • Originator Novan Inc
  • Class Antiacnes; Antiandrogens; Antibacterials; Antihypertensives; Antivirals; Free radicals; Nitrogen oxides; Non-opioid analgesics; Small molecules; Vasodilators
  • Mechanism of Action Androgen receptor antagonists; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Acne vulgaris
  • Phase II Genital warts
  • Discontinued Staphylococcal infections

Most Recent Events

  • 27 Jan 2017 Safety and efficacy data from the phase III NI-AC301 and NI-AC302 trials in Acne vulgaris released by Novan
  • 17 Jan 2017 Nitric oxide (SB 204) licensed to Sato Pharmaceutical in Japan
  • 14 Nov 2016 Novan announces intention to submit NDA to the US FDA in 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top